Partnered Discovery of High-Quality Antibody Drug Candidates. Company Presentation

Transcription

1 Partnered Discovery of High-Quality Antibody Drug Candidates Company Presentation

2 AbCheck s Unique Offering A unique source of human antibodies with one of the industry's most versatile technology platforms Antibodies for therapeutic application Antibodies with biological function Pure partnered-discovery provider Provider of exclusive sequences 2

3 Corporate Overview Top partner for antibody discovery and optimization A reliable source in the identification of novel, medically relevant antibodies against any target using one of the industry's most versatile technology platforms, validated through several products in the clinic High-quality, high-value antibodies based on cutting-edge in vitro and in vivo techniques, that integrates antibody screening and optimization platforms Dual offering of natural & engineered libraries, providing both phage and yeast display options and exclusive antibody sequences Only provider of rabbit mass humanization 3

4 AbCheck Corporate Background Leadership with substantial expertise in the biopharmaceutical industry Validation through several clinical programs AbCheck is a fully-owned subsidiary of Affimed (Nasdaq: AFMD) AbCheck retains a maximum level of independence Dr. Volker Lang Managing Director Dr. Vera Molkenthin Chief Scientist Dr. Oleh Petriv VP New Technology No shared labs or location. USA based business development and marketing division EXPERIENCE IN DISCOVERY PLATFORMS THROUGH Scil Technology COSMIX 4

5 Application: Immune Checkpoints Antibodies targeting Immune Checkpoints are powerful immuno-activators and have shown impressive results in various cancer indications AbCheck has identified anti-checkpoint IgGs with in vivo activity using its AbSieve technology 5

6 Application: Opportunity in Advancing Therapeutic Area New therapeutic approaches on the rise that use antibodies or fragments as components Technology platform is particularly well suited to deliver single-chain variable fragments as targeting elements rapidly Natural Human Library has delivered highly specific scfv with affinities in the single digit nanomolar range Chimeric Antigen Receptor (CAR) 6

7 Application: MHC Peptide Complexes MHC complexes display intracellular peptides on the surface of cells and alert the immune system to ongoing tumorigenic processes inside a cell Antibodies specifically targeting MHC-peptide complexes open up the therapeutic drug target space to otherwise unattainable tumorspecific cytosolic proteins AbCheck isolated peptide-specific antibodies against MHC complexes in a pilot study 7

8 Our Current Track Record Over 40 Successful Antibody Discovery Projects 8

9 Technology Suite Partnered Discovery of High-Quality Antibody Drug Candidates

10 What We Offer to Partners AbCheck s suite of antibody technologies Naïve Human Mass Humanization AbSieve AbAccel Human Antibody Libraries Selection Optimization Provides partners with various options for The de novo discovery of antibodies against virtually all targets in scfv, IgG or bi-specific formats Unique sources of human antibodies through natural, immunized and smartly-engineered libraries Next-generation Yeast Display capability The optimization of existing antibody-based drug candidates 10

11 AbCheck s Commitment to Meeting Industry Demands Industry Needs AbCheck s Solution Desire to identify specific antibodies with high developability potential Naïve Human Libraries Desire to use in vivo generated antibodies and humanize them consistently Mass Humanization Desire to work in final drug format AbSieve Desire to optimize drug-like properties of antibody candidates AbAccel 11

12 Technology Suite - Libraries Partnered Discovery of High-Quality Antibody Drug Candidates

13 The Human Antibody Library Human sequences Largest structural diversity Delivers high affinity and highly specific antibodies without optimizations Low immunogenicity by nature Used by AbCheck since 2010 with proven and robust performance 13

14 Mass Humanization A novel approach to human antibody discovery Human frameworks and germlined CDRs Combining the power of in vivo immunization with the best of in vitro engineering and in silico computational optimization Special potential for difficult targets Immunized Libraries Computational Design In Vitro Selection 14

15 Mass Humanization AbCheck s Mass Humanization delivers antibodies that are more Human Immunized Rabbits Classic Humanization Approach Humanized Library Rabbit Antibody Library / Hybridomas VH VL Selected Rabbit Antibody Lead Candidate Lead Candidate VH VL 15

16 Technology Suite - AbSieve Selection in Final Drug Format Partnered Discovery of High-Quality Antibody Drug Candidates

17 AbSieve TM Next Generation Yeast Display for Advanced Selection Potential IgG (bivalent) Recommended for selections of IgG and bi-specifics Screening in final drug format Target specific VH/VL pools Yeast Display Bi-specific formats AbSieve avoids drop-outs due to reformatting Any other formats 17

18 Technology Suite - AbAccel Optimization Partnered Discovery of High-Quality Antibody Drug Candidates

19 AbAccel High-End Lead Optimization AbCheck Premium Optimization Method Quality Maintains beneficial antibody properties Based on a proprietary algorithm Multi-factor antibody optimization in a single process Upgrade and final polishing before development To meet special affinity requirements To improve developability 19

20 AbAccel Optimizes Affinity While Preserving Other Drug-Relevant Properties AbAccel repeatedly achieved two logs improvement in affinity with optimal species cross-reactivity and thermal stability Optimized Candidates Complete permutation of 50 CDR positions enables paratope delineation Human KD (log 10 of nm) Candidate Clones for AbAccel Optimization 20

21 Integrated Customer Project Partnered Discovery of High-quality Antibody Drug Candidates

22 Integrated Process Approach for Projects at AbCheck Client specifications for target & lead antibodies Joint project team defining project objectives and work plan Work progressed at AbCheck with weekly updates Leads returned to client for further development Client AbCheck/Joint Project Team Client Antigen Antibody profile Define research milestones Lead Candidate Discovery (scfv or IgG format) Milestone Achievement Weekly Communication Data and IP transfer Exclusive Antibody Sequence for Drug development 22

23 Tailor Made Workflows Detailed project plans including milestones are defined in a joint project team Weekly updates ensure maximal transparency Human Antibody Libraries ScFv, IgG or other format Naïve or immunized repertoires QC tested Antigen Purified protein Expression cell lines Phage Panning/Sorting Up to 8 parallel selections Cell panning Epitope-focused selection Species Cross-reactivity Deep screen Single colony lysates ELISA/Flow Cytometry Thermal stability Functional assays Transfer of VH/VL sequences to customer Confirmed Leads Binding & specificity validation BIACORE Cell-based assays Functional assays Verified Hits Bacterial/eukaryotic re-cloning scfv, IgG or other format Sequencing & purification 23

24 AbCheck Summary One of the most versatile therapeutic antibody platforms that provides a customizable way to your lead candidate Accessible through a pure partnered-discovery model Experts in: Antibody discovery Lead optimization & humanization Successfully validated platform AbCheck antibodies already in clinical and preclinical development Seeking more partners for drug discovery and novel technology to add further capabilities